58 results
20-F/A
2023 FY
BLRX
BioLineRx Ltd.
26 Mar 24
Annual report (foreign) (amended)
4:57pm
and other pharmacovigilance activities conducted under an established quality system, advertising, packaging and labelling, patient package leaflets … package is designed to reduce the risk of excessively risk-oriented behavior, to discourage initiatives focused on short-term results which might
6-K
EX-99
BLRX
BioLineRx Ltd.
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
submission. During the pre-NDA meeting, the FDA agreed that the proposed data package is sufficient to support an NDA submission.
In March 2022, we
6-K
EX-99
BLRX
BioLineRx Ltd.
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
, is sufficient to support an NDA submission. During the pre-NDA meeting, the FDA agreed that the proposed data package is sufficient to support an NDA
6-K
EX-99
BLRX
BioLineRx Ltd.
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
, is sufficient to support an NDA submission. During the pre-NDA meeting, the FDA agreed that the proposed data package is sufficient to support an NDA
6-K
EX-99
2u4k 4pyimupwr
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
424B5
5tg74cu
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
av99vwy
16 Aug 22
BioLineRx Reports Second Quarter 2022 Financial Results
7:19am
6-K
EX-99
d4vy0gqdv w720d
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
mo8iqm7o4q3nvuakjvd7
11 May 22
BioLineRx Reports First Quarter 2022 Financial Results
7:14am
6-K
EX-99
zclwhs2fpe96gi
16 Mar 22
BioLineRx Reports Fourth Quarter 2021 Financial Results
7:11am
6-K
EX-99
0ndz ua9lgntp
18 Jan 22
BioLineRx Announces Successful Completion of Pre-NDA
7:11am
6-K
EX-99
ehhujq0zgp6yjq 22e
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
6-K
EX-1
qa9whm
28 May 19
Current report (foreign)
7:04am